{
    "clinical_study": {
        "@rank": "142882", 
        "arm_group": [
            {
                "arm_group_label": "Anacetrapib", 
                "arm_group_type": "Experimental", 
                "description": "Participants receive anacetrapib 100 mg orally once daily for 12 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Participants receive placebo orally once daily for 12 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and effect of anacetrapib on low-density\n      lipoprotein-cholesterol (LDL-C) when added to ongoing lipid-lowering therapy. The primary\n      hypothesis is that treatment with anacetrapib 100 mg for 12 weeks will lower LDL-C to a\n      greater extent than treatment with placebo."
        }, 
        "brief_title": "Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hyperlipoproteinemia Type II", 
            "Homozygous Familial Hypercholesterolemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypercholesterolemia", 
                "Hyperlipoproteinemia Type II", 
                "Hyperlipoproteinemias"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with HoFH by genotyping\n\n          -  If female, cannot be of reproductive potential\n\n          -  Have been stabilized on statin monotherapy or statin therapy coadministered\n\n        with other lipid medications for at least 6 weeks\n\n        Exclusion Criteria:\n\n          -  Severe chronic heart failure defined by New York Heart Association\n\n        (NYHA) Classes III or IV\n\n          -  Uncontrolled cardiac arrhythmias, myocardial infarction (MI), percutaneous coronary\n             intervention (PCI), coronary arterial by-pass graft (CABG), unstable angina or stroke\n             within 3 months prior to Visit 1 or has planned procedures scheduled within first 12\n             weeks of study\n\n          -  Uncontrolled endocrine or metabolic disease known to influence serum\n\n        lipids or lipoproteins\n\n          -  Active or chronic hepatobiliary or gall bladder disease\n\n          -  History of ileal bypass, gastric bypass, or other significant condition\n\n        associated with malabsorption\n\n          -  Human immunodeficiency virus (HIV) positive\n\n          -  Donated blood products or has had phlebotomy of >300 mL within 8 weeks or intends to\n             donate 250_mL of blood products or receive blood products within the projected\n             duration of the study\n\n          -  Taking medications that are potent inhibitors or inducers of cytochrome P450 3A4\n             (CYP3A4), including but not limited to cyclosporine, systemic itraconazole or\n             ketoconazole, erythromycin, clarithromycin, or telithromycin, nefazodone, protease\n             inhibitors, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, St John's\n             wort) or has discontinued treatment <3 weeks prior. Consumption of >1 liter of\n             grapefruit juice per day is also prohibited.\n\n          -  Currently participating or has participated in a study with an investigational\n             compound or device within 3 months\n\n          -  Consume more than 2 alcoholic drinks per day\n\n          -  Receiving treatment with systemic corticosteroids or systemic anabolic agents"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01841684", 
            "org_study_id": "0859-042", 
            "secondary_id": "2012-002434-37"
        }, 
        "intervention": [
            {
                "arm_group_label": "Anacetrapib", 
                "description": "100 mg tablet orally, once daily for 12 weeks", 
                "intervention_name": "Anacetrapib", 
                "intervention_type": "Drug", 
                "other_name": "MK-0859"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo for anacetrapib orally, once daily for 12 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Oxazolidinones"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "HoFH", 
        "lastchanged_date": "February 17, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percent change from Baseline in Low-density Lipoprotein-Cholesterol (LDL-C) using beta-quantification  method", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }, 
            {
                "measure": "Number of Participants with Alanine Transaminase (ALT) or Aspartate Aminotransferase  (AST) Consecutive Elevations \u22653x Upper Limit of Normal (ULN)", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Number of Participants with Creatine Phosphokinase Elevations \u226510xULN with or without  Muscle Symptoms", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Number of Participants with Sodium, Chloride, or Bicarbonate Elevations >ULN or  Potassium Levels <Lower Limit of Normal (LLN)", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Number of Participants with Pre-specified Adjudicated Cardiovascular Serious Adverse  Events or Death from Any Cause", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Number of Participants with Significant Increase in Blood Pressure", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "removed_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Germany", 
                "Israel", 
                "Italy", 
                "United Kingdom", 
                "Norway"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01841684"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percent Change from Baseline in High-density Lipoprotein-cholesterol (HDL-C)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }, 
            {
                "measure": "Percent Change from Baseline in Apolipoprotein A-I (apoA-I)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}